Nasdaq
$6.65▲ 0.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $171.6MShares out 25.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 9.30After-hours26.10.01 05:154Ownership#●●●#●●●
PRECISION BIOSCIENCES INC
Insider Stanley Frankel of Precision BioSciences reported a change in his beneficial ownership of company securities effective September 28, 2026. This filing serves as a formal disclosure of insider stock activity via Form 4.…more
$6.65+0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 20:004Ownership
PRECISION BIOSCIENCES INC
Insider Melinda Brown of Precision BioSciences reported a change in beneficial ownership of company securities effective September 25, 2026. This filing serves as a formal disclosure of the insider's stock holdings.…more
$6.65+0.30%vs prev closeView filingShare - 9.29Pre-market26.09.29 20:004Ownership
PRECISION BIOSCIENCES INC
Insider Geno J. Germano of Precision BioSciences reported a change in beneficial ownership of securities effective September 25, 2026. This filing serves as the official Form 4 disclosure of the insider's equity transaction.…more
$6.65+0.30%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.27Pre-market26.08.27 21:07#●●●#●●●#●●●
iECURE Reports Positive Phase 1/2 Data for OTC Deficiency Gene Therapy
iECURE has completed dosing for its Phase 1/2 trial of ECUR-506, reporting a 74% reduction in annualized hyperammonemic crises in the low-dose cohort. While the therapy was generally well-tolerated, one participant death occurred, which the company attributed to the underlying disease progression.…more
$6.65+0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 8.24Pre-market26.08.24 19:07
●●●●●●●● ●●●●● ●●●●●●
Precision BioSciences has successfully dosed the first patient in its Phase 1/2 clinical trial for PBGENE-DMD, a gene-editing therapy for Duchenne muscular dystrophy. The company aims to restore functional dystrophin protein and expects to report initial safety data by the end of 2026.…more
$6.65+0.30%vs prev closeShareBenzinga - 8.20Pre-market26.08.20 21:03
●●●●●●●● ●●●●● ●●●●●●
iECURE will present updated safety and metabolic control data from its Phase 1/2 trial of ECUR-506 for neonatal-onset OTC deficiency on August 27. The therapy utilizes the ARCUS nuclease platform licensed from Precision BioSciences.…more
$6.65+0.30%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report